Results 231 to 240 of about 2,036,299 (361)

Efficacy of Ultrasonic Mass Survey for Abdominal Organs (Focus on Analysis of Malignant Neoplasm Cases)

, 1994
本藤 和子, 大倉 佳代, 後藤 由美子, 森元 栄子, 町原 美希子, 平尾 真一, 山部 弘恵, 長野 勝広, 木場 博幸, 佐渡 美智代, 三原 修一, 小山 和作   +11 more
openalex   +2 more sources

Lymphoid neoplasms

Hematology, 2015
Jumoke, Okikiolu, Christopher, McNamara
openaire   +2 more sources

ATF4‐mediated stress response as a therapeutic vulnerability in chordoma

Molecular Oncology, EarlyView.
We screened 5 chordoma cell lines against 100+ inhibitors of epigenetic and metabolic pathways and kinases and identified halofuginone, a tRNA synthetase inhibitor. Mechanistically halofuginone induces an integrated stress response, with eIF2alpha phosphorylation, activation of ATF4 and its target genes CHOP, ASNS, INHBE leading to cell death ...
Lucia Cottone, James Dunford, Eleanor Calcutt, Vicki Gamble, Filiz Senbabaoglu Aksu, Lorena Ligammari, Georgina Wherry, Giorgia Gaeta, John C. Christianson, Adrienne M. Flanagan, Udo Oppermann, Adam P. Cribbs   +11 more
wiley   +1 more source

Germline rare variants in cancer susceptibility genes and subsequent neoplasm risk after childhood cancer. [PDF]

J Natl Cancer Inst
Zamani SA, Karyadi DM, Hartley SW, Gibson TM, Sampson JN, Kraft P, Chanock SJ, Morton LM.   +7 more
europepmc   +1 more source

DETECTION OF T CELL CLONALITY WITH 13-COLOR AND 15 PARAMETERS USING FLOW CYTOMETRY - IMPORTANT TOOL IN THE DIAGNOSIS OF MATURE T CELL NEOPLASMS

LC Bento, FA Sousa, EX Souto, NS Bacal
openalex   +1 more source

A subset of MMR‐proficient colon cancers responds to neoadjuvant immunotherapy

Molecular Oncology, EarlyView.
Tan et al. reveal that a distinct subset of early‐stage pMMR colon cancers can respond to neoadjuvant immunotherapy. In the NICHE‐2 trial, responders (26%) were characterized by chromosomal instability, TP53 mutations, and proliferative cell‐cycle programs, whereas nonresponders showed metabolic and stromal reprogramming with TGF‐β‐driven ...
Eleonora Piumatti, Giovanni Germano, Pietro Paolo Vitiello, Alberto Bardelli   +3 more
wiley   +1 more source

Recurrence after ablation of Bethesda IV thyroid nodule: report of two cases. [PDF]

Gland Surg
Ma J, Zhang B.
europepmc   +1 more source

A real-world retrospective analysis to evaluate the efficacy and safety of surufatinib in the treatment of advanced neuroendocrine neoplasms in China

Shutong Liu, Yumeng Wang, Sen Hong, Lianru Zhang, Baorui Liu, Qin Liu   +5 more
openalex   +1 more source

Developing evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities

Molecular Oncology, EarlyView.
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg, Joachim von Braun, Julio Celis, Anton Berns, Michael Baumann, Tit Albreht, Nancy Abou‐Zeid, Vanderlei Bagnato, Christian Brandts, Chien‐Jen Chen, Massimiliano di Pietro, Manjit Dosanjh, Thomas Dubois, Alexander Eggermont, Angelika Eggert, Ingemar Ernberg, Sara Faithfull, Johannes Förner, Stefan Fröhling, Manuel Heitor, Leroy Hood, Wei Jiang, Bengt Jönsson, Ravi Kannan, Maria Leptin, Su Li, Peter Lindgren, Douglas Lowy, Jun Ma, Alex Markham, Péter Nagy, Simon Oberst, M. Iqbal Parker, Danielle Rodin, Kevin Ryan, Joachim Schüz, Richard Sullivan, Josep Tabernero, Peter Turkson, Oliver Várhelyi, Harold Varmus, Chijie Wang, Elisabete Weiderpass, Nils Wilking   +43 more
wiley   +1 more source

Care for patients with hematologic neoplasms: contextual analysis resulting from a scoping review. [PDF]

Rev Bras Enferm
Azevedo IC, Silva LACD, Augusto EA, Azevedo VD, Santos VEP, Oliveira ACS.   +5 more
europepmc   +1 more source